Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...
CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...
A research team investigates how genome editing can be harnessed to accelerate cassava breeding and improve key traits.
Researchers from the J. Craig Venter Institute (JCVI), the Friedrich-Loeffler-Institut (FLI), and the International Livestock ...
A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon ...
Exploration of dsRNA interactome using the K1 antibody and functional studies using CRISPR-Cas9 knockout screening of these dsRBP candidates elucidate the role of dsRNA interactome in immune ...
The goal of genome editing technology is to develop strategies for the correction of those mutations that are responsible of ...
In this article, we are going to look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The ...
Cas9-induced frameshift mutations can result in PTC-containing mutant mRNAs that are recognized by the NMD machinery and degraded. Cas13d, an endoribonuclease, is guided to specific transcripts by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback